

CITATION REPORT

List of articles citing

Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity

DOI: 10.1016/s0149-2918(00)90004-3
Clinical Therapeutics, 2000, 22, 685-708.

Source: <https://exaly.com/paper-pdf/32018596/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
521	Metabolic complications of antiretroviral therapy in children. 382-396		1
520	Prevalence of endocrine dysfunction in HIV-infected men. 2000 , 54, 294-5		11
519	Editorial comment. <i>Clinical Therapeutics</i> , 2000 , 22, 898	3.5	1
518	Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity. <i>Clinical Therapeutics</i> , 2000 , 22, 911-36; discussion 898	3.5	165
517	Mitochondrial toxicity and HIV therapy. 2001 , 77, 158-73		147
516	Continuing HIV therapy in the ICU. 2001 , 5, 247-8		8
515	Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipotrophy. 2001 , 15, 1801-9		150
514	Clinical perspectives on HIV-associated lipodystrophy syndrome: an update. 2001 , 15, 1917-30		68
513	Hyperlipidemia and inhibitors of HIV protease. 2001 , 4, 99-103		21
512	Thrombotic thrombocytopenic purpura associated with clopidogrel administration: case report and brief review. 2001 , 322, 170-2		10
511	Mitochondrial Toxicity Associated with Nucleoside Reverse Transcriptase Inhibitor Therapy. 2001 , 3, 553-560		10
510	Metabolic Complications of HIV and AIDS. 2001 , 3, 183-192		2
509	AIDS and AIDS-treatment neuropathies. 2001 , 1, 533-8		9
508	British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. 2001 , 2, 276-313		91
507	Mitochondrial dna depletion, oxidative stress, and mutation: mechanisms of dysfunction from nucleoside reverse transcriptase inhibitors. 2001 , 81, 777-90		135
506	Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. February 5, 2001. 2001 , 2, 227-306		21
505	Differential incorporation and removal of antiviral deoxynucleotides by human DNA polymerase gamma. 2001 , 276, 23616-23		181

504	Alcohol use and HIV pharmacotherapy. 2002 , 18, 757-70	57
503	Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature. 2002 , 34, 838-46	152
502	HIV therapies and atherosclerosis: answers or questions?. 2002 , 22, 1758-60	4
501	Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors. 2002 , 16, 2165-73	158
500	HIV-associated sensory neuropathies. 2002 , 16, 2105-17	170
499	Drugs and steatohepatitis. 2002 , 22, 185-94	160
498	Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. 2002 , 46, 716-23	377
497	Exposure to dideoxynucleosides is reflected in lowered mitochondrial DNA in subcutaneous fat. 2002 , 30, 271-7	98
496	HIV/HCV co-infection: clinical and therapeutic challenges. 2002 , 16, 1419-20	2
495	Adefovir nephrotoxicity and mitochondrial DNA depletion. 2002 , 33, 574	12
494	Antiretroviral drug toxicity -- a challenge for the hepatologist?. 2002 , 36, 283-94	94
493	Pharmacodynamic activity of drugs and ecotoxicology--can the two be connected?. 2002 , 131, 105-15	126
492	Management of hepatitis C in human immunodeficiency virus-infected patients. 2002 , 34, 452-9	2
491	Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. 2002 , 346, 811-20	537
490	Fatal lactic acidosis associated with antiretroviral therapy. 2002 , 16, 515-7	
489	Phase I trial of a therapeutic HIV type 1 vaccine, Vacc-4x, in HIV type 1-infected individuals with or without antiretroviral therapy. 2002 , 18, 1357-65	33
488	Trizivir. 2002 , 3, 619-24	2
487	Mitochondrial dysfunction and antiretroviral nucleoside analog toxicities: what is the evidence?. 2002 , 1, 397-412	85

486	Discovery of second generation quinazolinone non-nucleoside reverse transcriptase inhibitors of HIV-1. 2002 , 40, 63-105	11
485	DPC 817: a cytidine nucleoside analog with activity against zidovudine- and lamivudine-resistant viral variants. 2002 , 46, 1394-401	47
484	Estado actual del tratamiento de la infecci3n por el VIH. 2002 , 9, 684-695	
483	Combinations against combinations: associations of anti-HIV 1 reverse transcriptase drugs challenged by constellations of drug resistance mutations. 2002 , 3, 73-95	22
482	Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors. 2002 , 54, 37-45	106
481	Fanconi syndrome and renal failure induced by tenofovir: a first case report. 2002 , 40, 1331-3	304
480	Gynecomastia in male HIV patients MRI and US findings. 2002 , 26, 309-13	10
479	Mitochondrial diabetes: pathophysiology, clinical presentation, and genetic analysis. 2002 , 115, 66-70	49
478	Reply. 2002 , 35, 500-500	
477	AIDS and AIDS-treatment neuropathies. 2002 , 6, 125-30	9
476	Depletion of the other genome-mitochondrial DNA depletion syndromes in humans. 2002 , 80, 389-96	44
475	Fast relapse and high drop out rate of 48 weeks daily interferon monotherapy in HIV-infected patients with chronic hepatitis C. 2002 , 2, 17	
474	Body composition changes in protease inhibitor-naive HIV-infected patients treated with two nucleoside reverse transcriptase inhibitors. 2002 , 3, 85-90	30
473	Sample size in trials of hepatitis C. 2002 , 35, 500	
472	Mitochondrial toxicity in HIV-HCV coinfection: It depends on the choice of antiretroviral drugs?. 2002 , 35, 500-1	8
471	Endoscopic screening for esophageal varices in cirrhotic patients. 2002 , 35, 501-2	27
470	L-carnitine reduces lymphocyte apoptosis and oxidant stress in HIV-1-infected subjects treated with zidovudine and didanosine. 2002 , 4, 391-403	58
469	A cell-based approach for the early assessment of the phospholipidogenic potential in pharmaceutical research and drug development. 2003 , 19, 161-76	62

468	Antiretroviral Therapy-associated Serious and Life-threatening Toxicities. 2003 , 5, 429-438	2
467	Mitochondrial DNA replication, nucleoside reverse-transcriptase inhibitors, and AIDS cardiomyopathy. 2003 , 45, 305-18	35
466	Beneficial effects of L-carnitine in myoblastic C2C12 cells. Interaction with zidovudine. 2003 , 65, 1483-8	31
465	Metabolic acidosis and hepatic steatosis in two HIV-infected patients on stavudine (d4T) treatment. 2003 , 34, 64-9	17
464	Evaluation of mitochondrial DNA content and enzyme levels in tenofovir DF-treated rats, rhesus monkeys and woodchucks. 2003 , 58, 217-25	55
463	Mitochondrial dysfunction and nucleoside reverse transcriptase inhibitor therapy: experimental clarifications and persistent clinical questions. 2003 , 58, 189-97	65
462	Depletion of mitochondrial DNA in HIV-1-infected patients and its amelioration by antiretroviral therapy. 2003 , 70, 497-505	89
461	Comparative effects of adefovir and selected nucleoside inhibitors of hepatitis B virus DNA polymerase on mitochondrial DNA in liver and skeletal muscle cells. 2003 , 10, 50-4	20
460	British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. 2003 , 4, 1-41	127
459	Leber's hereditary optic neuropathy triggered by antiretroviral therapy for human immunodeficiency virus. 2003 , 17, 312-7	67
458	Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. 2003 , 2, 812-22	362
457	Impaired oxygen on-kinetics in persons with human immunodeficiency virus are not due to highly active antiretroviral therapy. 2003 , 84, 1831-8	19
456	Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase. 2003 , 42, 14711-9	183
455	Structural determinants in human DNA polymerase gamma account for mitochondrial toxicity from nucleoside analogs. 2003 , 329, 45-57	81
454	The selective in vitro cytotoxicity of carcinoma cells by AZT is enhanced by concurrent treatment with delocalized lipophilic cations. 2003 , 198, 59-68	31
453	Mitochondrion-mediated apoptosis in HIV-1 infection. 2003 , 24, 298-305	43
452	Accumulation of mitochondrial DNA mutations in human immunodeficiency virus-infected patients treated with nucleoside-analogue reverse-transcriptase inhibitors. 2003 , 72, 549-60	80
451	Nucleoside analogues and neuropathy in the era of HAART. 2003 , 26, 195-207	69

450	Assessment of precision and concordance of quantitative mitochondrial DNA assays: a collaborative international quality assurance study. 2003 , 27, 97-110	42
449	Site-specific differences in the action of NRTI drugs on adipose tissue incubated in vitro with lymphoid cells, and their interaction with dietary lipids. 2003 , 135, 11-29	7
448	Lactic acidosis related to nucleoside therapy in HIV-infected patients. 2003 , 4, 1321-9	20
447	Idiosyncratic drug hepatotoxicity revisited: new insights from mechanistic toxicology. 2003 , 13, 3-20	33
446	Human Immunodeficiency Virus Infection: A Focus on Women. 2003 , 16, 170-181	
445	Nucleoside analogues and HIV: the combined cost to mitochondria. 2003 , 51, 1091-3	20
444	Early factors in successful anti-HIV treatment. 2003 , 2, 10-20	6
443	Imported Lassa fever in Germany: surveillance and management of contact persons. 2003 , 36, 1254-8	118
442	Tenofovir disoproxil fumarate. 2003 , 37, 849-59	61
441	HAART homes in on lymphocyte mitochondria in lactic acidosis. 2003 , 79, 344-344	78
440	Mitochondrial membrane hyperpolarization hijacks activated T lymphocytes toward the apoptotic-prone phenotype: homeostatic mechanisms of HIV protease inhibitors. 2003 , 170, 6006-15	68
439	Lactic acidosis in HIV infected patients: a systematic review of published cases. 2003 , 79, 340-3	71
438	Clinical review 159: Human immunodeficiency virus/highly active antiretroviral therapy-associated metabolic syndrome: clinical presentation, pathophysiology, and therapeutic strategies. 2003 , 88, 1961-76	96
437	Toward the development of a virus-cell-based assay for the discovery of novel compounds against human immunodeficiency virus type 1. 2003 , 47, 501-8	11
436	First-line therapy and mitochondrial damage: different nucleosides, different findings. 2003 , 4, 11-9	25
435	Factors associated with mitochondrial dysfunction in circulating peripheral blood lymphocytes from HIV-infected people. 2003 , 34, 32-6	25
434	Drug points: Fatal lactic acidosis associated with tenofovir. 2003 , 327, 711	16
433	Inherited mitochondrial DNA depletion. 2003 , 54, 153-9	25

432	[Fatty liver and increased serum lactate in a woman with HIV]. 2003 , 128, 81-4	6
431	Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. 2003 , 17, 1329-38	197
430	Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals. 2003 , 17, 2159-68	107
429	Defective mitochondrial DNA replication and NRTIs: pathophysiological implications in AIDS cardiomyopathy. 2003 , 284, H1-9	30
428	Mitochondrial DNA levels in fat and blood cells from patients with lipodystrophy or peripheral neuropathy and the effect of 90 days of high-dose coenzyme Q treatment: a randomized, double-blind, placebo-controlled pilot study. 2004 , 39, 1371-9	29
427	Mitochondrial expression of the human equilibrative nucleoside transporter 1 (hENT1) results in enhanced mitochondrial toxicity of antiviral drugs. 2004 , 279, 4490-7	111
426	Improvement in lipodystrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. 2004 , 38, 263-70	157
425	The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities. 2004 , 38, 743-53	115
424	Pharmacologic perspectives for once-daily antiretroviral therapy. 2004 , 38, 1924-34	14
423	Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. 2004 , 4, 895-919	65
422	Changes in mitochondrial DNA copy number in blood cells from HIV-infected patients undergoing antiretroviral therapy. 2004 , 20, 271-3	33
421	Prospective evaluation of blood concentration of mitochondrial DNA as a marker of toxicity in 157 consecutively recruited untreated or HAART-treated HIV-positive patients. 2004 , 84, 908-14	47
420	Direct, DNA pol-gamma-independent effects of nucleoside reverse transcriptase inhibitors on mitochondrial bioenergetics. 2004 , 4, 217-28	23
419	Human immunodeficiency virus and hepatitis C virus coinfection: epidemiology, natural history, therapeutic options and clinical management. 2004 , 32, 33-46	79
418	Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine. 2004 , 39, 311-7	112
417	Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014). 2004 , 20, 1103-14	37
416	Triple nucleoside reverse transcriptase inhibitor therapy in children. 2004 , 6, 147-59	16
415	Activation of c-Jun N-terminal kinase mediates gp120IIIB- and nucleoside analogue-induced sensory neuron toxicity. 2004 , 188, 246-246	

414	Management of chronic hepatitis C in patients co-infected with HIV: focus on safety considerations. 2004 , 27, 7-24	10
413	Cholestasis in HIV-infected patients. 2004 , 8, 213-28, viii-ix	8
412	DNA polymerase gamma, the mitochondrial replicase. 2004 , 73, 293-320	347
411	Efavirenz for HIV-1 infection in adults: an overview. 2004 , 2, 671-84	18
410	Hyperlactataemia and lactic acidosis in HIV-infected patients receiving antiretroviral therapy. 2004 ,	
409	Activation of c-Jun N-terminal kinase mediates gp120IIIB- and nucleoside analogue-induced sensory neuron toxicity. 2004 , 188, 246-53	39
408	Novel mechanism of enhanced nociception in a model of AIDS therapy-induced painful peripheral neuropathy in the rat. 2004 , 107, 147-58	96
407	Role of mitochondria in HIV lipotrophy: insight into pathogenesis and potential therapies. 2004 , 4, 111-8	41
406	Impact of mitochondrial regulation of apoptosis on the pathogenesis and treatment of HIV-1-induced immunodeficiency. 2004 , 4, 235-54	8
405	Molecular insights into NRTI inhibition and mitochondrial toxicity revealed from a structural model of the human mitochondrial DNA polymerase. 2004 , 4, 203-13	26
404	Cumulative insults to mitochondrial function may promote the emergence of Syndrome X and diabetes mellitus in HIV/HCV co-infected patients. 2004 , 4, 175-84	7
403	Direct effects of nucleoside reverse transcriptase inhibitors on rat cardiac mitochondrial bioenergetics. 2004 , 4, 193-202	22
402	Mitochondrial injury in the pathogenesis of antiretroviral-induced hepatic steatosis and lactic acidemia. 2004 , 4, 95-109	26
401	Mitochondrial dysfunction in AIDS and its treatment. 2004 , 4, 763-77	64
400	[Nucleoside induced hepatopathy in HIV patients. Diagnostic value of liver biopsy assessment]. 2004 , 25, 406-11	0
399	Antiretrovirals, Part II: focus on non-protease inhibitor antiretrovirals (NRTIs, NNRTIs, and fusion inhibitors). 2004 , 45, 524-35	33
398	Mitochondrial abnormalities in HIV-infected lipotrophic patients treated with antiretroviral agents. 2004 , 37, 1477-88	24
397	Tolerability and safety of HIV protease inhibitors in adults. 2004 , 37, 1111-24	40

396	Lack of recurrence of hyperlactatemia in HIV-infected patients switched from stavudine to abacavir or zidovudine. 2004 , 36, 935-42	19
395	Chronic Exposure of the Blood-Brain Barrier to Highly Active Antiretroviral Therapy. 2004 , 12, 158-162	1
394	The HIV-1 nucleoside reverse transcriptase inhibitors stavudine and zidovudine alter adipocyte functions in vitro. 2004 , 18, 2127-36	78
393	Aerobic Exercise Dysfunction in Human Immunodeficiency Virus: A Potential Link to Physical Disability. 2004 , 84, 655-664	34
392	¹³ C-methionine breath test detects distinct hepatic mitochondrial dysfunction in HIV-infected patients with normal serum lactate. 2005 , 40, 149-54	29
391	Mitochondrial toxicity of nucleoside analogues: mechanism, monitoring and management. 2005 , 2, 1-11	13
390	Reductions in stavudine dose might ameliorate mitochondrial-associated complications without compromising antiviral activity. 2005 , 6, 197-202	24
389	Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study. 2005 , 19, 1341-9	114
388	Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine. 2005 , 19, 15-23	123
387	Brain mitochondrial injury in human immunodeficiency virus-seropositive (HIV+) individuals taking nucleoside reverse transcriptase inhibitors. 2005 , 11, 356-64	125
386	British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005). 2005 , 6 Suppl 2, 1-61	120
385	HAART-related nephropathies in HIV-infected patients. 2005 , 67, 393-403	87
384	Fatal exacerbation of peripheral neuropathy during lamivudine therapy: evidence for iatrogenic mitochondrial damage. 2005 , 60, 806-10	13
383	Chemokines: integrators of pain and inflammation. 2005 , 4, 834-44	199
382	Hyperlactataemia and lactic acidosis in HIV-infected patients receiving antiretroviral therapy. 2005 , 24, 5-15	31
381	HIV-associated lipodystrophy syndrome: A review of clinical aspects. 2005 , 16, 233-43	46
380	Metabolic complications of antiretroviral therapy in children. 2005 , 319-333	
379	Does mitochondrial dysfunction during antiretroviral therapy in human immunodeficiency virus infection suggest antioxidant supplementation as a beneficial option?. 2005 , 10, 113-9	10

378	Modification of the incidence of drug-associated symmetrical peripheral neuropathy by host and disease factors in the HIV outpatient study cohort. 2005 , 40, 148-57	128
377	Anti-human immunodeficiency virus type 1 activity and resistance profile of 2'- β -D-ribofuranosyl-5'- α -L-uridylylthymidine in vitro. 2005 , 49, 3355-60	43
376	Mitochondrial dysfunction induces triglyceride accumulation in 3T3-L1 cells: role of fatty acid beta-oxidation and glucose. 2005 , 46, 1133-49	116
375	Drug-induced mitochondrial toxicity. 2005 , 1, 655-69	120
374	Coinfection with HIV and hepatitis C virus in injection drug users and minority populations. 2005 , 41 Suppl 1, S7-13	36
373	Oxygen consumption by cultured human cells is impaired by a nucleoside analogue cocktail that inhibits mitochondrial DNA synthesis. 2005 , 5, 154-61	8
372	Mitochondrial DNA depletion in adipose tissue of HIV-infected patients with peripheral lipodystrophy. 2005 , 33, 60-4	39
371	HIV Infection-Related Cachexia and Lipodystrophy. 2006 , 407-428	1
370	Treatment of AIDS Anorexia-Cachexia Syndrome and Lipodystrophy. 2006 , 429-456	1
369	Protective effect of acetyl-L-carnitine against oxidative stress induced by antiretroviral drugs. 2006 , 580, 6612-6	19
368	[Mitochondrial cytopathies associated with HIV infection]. 2006 , 162, 62-70	0
367	In silico search of putative adverse drug reaction related proteins as a potential tool for facilitating drug adverse effect prediction. 2006 , 164, 104-12	46
366	DNA polymerase gamma in mitochondrial DNA replication and repair. 2006 , 106, 383-405	216
365	Cell culture models for the investigation of NRTI-induced mitochondrial toxicity. Relevance for the prediction of clinical toxicity. 2006 , 20, 535-46	49
364	Adverse effects of antiretroviral drugs on HIV-1-infected and -uninfected human monocyte-derived macrophages. 2006 , 42, 19-28	19
363	Tissue-specific associations between mitochondrial DNA levels and current treatment status in HIV-infected individuals. 2006 , 42, 435-40	53
362	A prospective study of hearing changes after beginning zidovudine or didanosine in HIV-1 treatment-naïve people. 2006 , 6, 28	30
361	Depletion of mitochondrial DNA copies/cell in peripheral blood mononuclear cells in HIV-1-infected treatment-naïve patients. 2006 , 7, 53-8	40

360	Long-term assessment of nevirapine-containing highly active antiretroviral therapy in antiretroviral-naïve HIV-infected patients: 3-year follow-up of the VIRGO study. 2006 , 7, 431-6	12
359	Quantitation of zidovudine triphosphate concentrations from human peripheral blood mononuclear cells by anion exchange solid phase extraction and liquid chromatography-tandem mass spectroscopy; an indirect quantitation methodology. 2006 , 831, 248-57	39
358	Mitochondrial AZT metabolism. 2006 , 58, 403-8	16
357	Upregulation of mitochondrial gene expression in PBMC from convalescent SARS patients. 2006 , 26, 546-54	30
356	Pharmacology of current and promising nucleosides for the treatment of human immunodeficiency viruses. 2006 , 71, 322-34	49
355	Recurrent pancreatitis in mitochondrial cytopathy. 2006 , 140, 2330-5	14
354	Emerging reverse transcriptase inhibitors for the treatment of HIV infection in adults. 2006 , 11, 217-30	4
353	Changes in body composition and mitochondrial nucleic acid content in patients switched from failed nucleoside analogue therapy to ritonavir-boosted indinavir and efavirenz. 2006 , 194, 642-50	28
352	Limitations of current antiretroviral agents and opportunities for development. 2006 , 12, 1065-74	8
351	Current HIV treatment guidelines--an overview. 2006 , 12, 1045-63	50
350	Understanding and avoiding antiretroviral adverse events. 2006 , 12, 1075-90	37
349	In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cells. 2006 , 50, 3824-32	55
348	Model for intracellular Lamivudine metabolism in peripheral blood mononuclear cells ex vivo and in human immunodeficiency virus type 1-infected adolescents. 2006 , 50, 2686-94	17
347	The transmission of OXPHOS disease and methods to prevent this. 2006 , 12, 119-36	37
346	CREB activation induced by mitochondrial dysfunction triggers triglyceride accumulation in 3T3-L1 preadipocytes. 2006 , 119, 1266-82	77
345	Mitochondrial disease in the offspring as a result of antiretroviral therapy. 2006 , 5, 373-81	16
344	Adverse effects of antiretroviral therapy in HIV-1 infected children. 2006 , 52, 244-8	31
343	In vitro antiretroviral activity and in vitro toxicity profile of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus infection. 2006 , 50, 625-31	40

342	Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. 2007 , 45, 111-9	201
341	Antimicrobial Pharmacodynamics in Theory and Clinical Practice. 2007 ,	13
340	Cardiovascular risks of antiretroviral therapies. 2007 , 58, 141-55	23
339	Apricitabine: a novel deoxycytidine analogue nucleoside reverse transcriptase inhibitor for the treatment of nucleoside-resistant HIV infection. 2007 , 18, 61-70	15
338	Abacavir sulfate/lamivudine/zidovudine fixed combination in the treatment of HIV infection. 2007 , 8, 477-83	5
337	InforMatrix nucleoside/nucleotide reverse transcriptase inhibitor $\text{C}^{\text{backbones}}$ 2007 , 8 Suppl 1, S37-47	2
336	Increased resting energy expenditure, fat oxidation, and food intake in patients with highly active antiretroviral therapy-associated lipodystrophy. 2007 , 292, E687-92	30
335	Characterization of rodent models of HIV-gp120 and anti-retroviral-associated neuropathic pain. 2007 , 130, 2688-702	136
334	Didanosine causes sensory neuropathy in an HIV/AIDS animal model: impaired mitochondrial and neurotrophic factor gene expression. 2007 , 130, 2011-23	33
333	The role of adipokines in relation to HIV lipodystrophy. 2007 , 21, 895-904	43
332	HIV and mitochondrial toxicity in children. 2008 , 61, 8-12	56
331	Antiretroviral therapy-associated toxicities in the resource-poor world: the challenge of a limited formulary. 2007 , 196 Suppl 3, S449-56	47
330	Absence of a universal mechanism of mitochondrial toxicity by nucleoside analogs. 2007 , 51, 2531-9	66
329	Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2'- $\text{C}^{\text{didehydro}}$ -3'- C^{deoxy} -4'- $\text{C}^{\text{ethynyl}}$ thymidine, a novel thymidine analog. 2007 , 51, 3870-9	16
328	Nucleoside and nucleotide analogue reverse transcriptase inhibitor toxicity: how much longer must we wield the sword?. 2007 , 1, 61-72	
327	Hepatitis C in HIV-positive patients--treatment and liver disease outcomes. 2007 , 41, 75-87	10
326	Concentrations of zidovudine- and lamivudine-triphosphate according to cell type in HIV-seronegative adults. 2007 , 21, 1849-54	23
325	Oxidative stress and toxicity induced by the nucleoside reverse transcriptase inhibitor (NRTI)--2'- $\text{C}^{\text{dideoxy}}$ cytidine (ddC): relevance to HIV-dementia. 2007 , 204, 29-38	42

324	Mitochondrial disorders among infants exposed to HIV and antiretroviral therapy. 2007 , 30, 845-59	13
323	Nucleoside and nucleotide reverse transcriptase inhibitors in children. 2007 , 27, 509-31	6
322	The role of mitochondrial and plasma membrane nucleoside transporters in drug toxicity. 2007 , 3, 705-18	21
321	Uridine supplementation antagonizes zalcitabine-induced microvesicular steatohepatitis in mice. 2007 , 45, 72-9	32
320	A brief overview of mechanisms of mitochondrial toxicity from NRTIs. 2007 , 48, 166-72	125
319	Mutagenicity of zidovudine, lamivudine, and abacavir following in vitro exposure of human lymphoblastoid cells or in utero exposure of CD-1 mice to single agents or drug combinations. 2007 , 48, 224-38	42
318	Relative mutagenic potencies of several nucleoside analogs, alone or in drug pairs, at the HPRT and TK loci of human TK6 lymphoblastoid cells. 2007 , 48, 239-47	21
317	Review article: drug hepatotoxicity. 2007 , 25, 1135-51	161
316	Effects of apricitabine and other nucleoside reverse transcriptase inhibitors on replication of mitochondrial DNA in HepG2 cells. 2007 , 76, 68-74	22
315	Idiosyncratic drug-induced liver injury: an overview. 2007 , 6, 673-84	137
314	HIV-1 reverse transcriptase inhibitors. 2007 , 75, 723-37	56
313	Alteration of mitochondrial oxidative capacity during porcine preadipocyte differentiation and in response to leptin. 2008 , 307, 83-91	22
312	Anti-adenoviral effect of anti-HIV agents in vitro in serotypes inducing keratoconjunctivitis. 2007 , 245, 1319-25	13
311	The prevalence and risk factors for abnormal liver enzymes in HIV-positive patients without hepatitis B or C coinfections. 2008 , 53, 1375-82	55
310	Pathogenesis and management of lipoatrophy. 2008 , 5, 55-63	4
309	Confirmation of the chromosome damaging effects of lamivudine in in vitro human peripheral blood lymphocytes. 2008 , 49, 328-33	12
308	Uridine supplementation antagonizes zidovudine-induced mitochondrial myopathy and hyperlactatemia in mice. 2008 , 58, 318-26	26
307	Recovery of fat following a switch to nucleoside reverse transcriptase inhibitor-sparing therapy in patients with lipoatrophy: results from the 96-week randomized ANRS 108 NoNuke Trial. 2008 , 9, 625-35	19

306	Impact of long-term treatment with neurotoxic dideoxynucleoside antiretrovirals: implications for clinical care in resource-limited settings. 2008 , 9, 731-7	11
305	Transcriptional profiles in CD8+ T cells from HIV+ progressors on HAART are characterized by coordinated up-regulation of oxidative phosphorylation enzymes and interferon responses. 2008 , 380, 124-35	37
304	Adenosine 3',5'-cyclic monophosphate (cAMP)-dependent phosphoregulation of mitochondrial complex I is inhibited by nucleoside reverse transcriptase inhibitors. 2008 , 226, 94-106	36
303	Mitochondrial DNA impairment in nucleoside reverse transcriptase inhibitor-associated cardiomyopathy. 2008 , 21, 990-6	9
302	A review of the pharmacokinetics of abacavir. 2008 , 47, 351-71	94
301	Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 reverse transcriptase. 2008 , 134, 124-46	108
300	Mitochondrial off targets of drug therapy. 2008 , 29, 361-6	79
299	Inhibition of reverse transcriptase activity of HIV by polysaccharides of brown algae. 2008 , 62, 303-7	118
298	Pyrimidine nucleoside depletion sensitizes to the mitochondrial hepatotoxicity of the reverse transcriptase inhibitor stavudine. 2008 , 172, 681-90	32
297	Design and profiling of GS-9148, a novel nucleotide analog active against nucleoside-resistant variants of human immunodeficiency virus type 1, and its orally bioavailable phosphonoamidate prodrug, GS-9131. 2008 , 52, 655-65	86
296	Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection. 2008 , 62, 879-88	68
295	Lymphocyte mitochondrial depolarization and apoptosis in HIV-1-infected HAART patients. 2008 , 48, 381-8	23
294	The mitochondrial pharmacogenomics of haplogroup T: MTND2*LHON4917G and antiretroviral therapy-associated peripheral neuropathy. 2008 , 8, 71-7	51
293	A novel role for mitochondria in regulating epigenetic modification in the nucleus. 2008 , 7, 1182-90	156
292	Bilateral lipomastia in men: a side effect of highly active antiretroviral therapy. 2008 , 16, 171-5	4
291	Distinct mechanisms for mitochondrial DNA loss in T and B lymphocytes from HIV-infected patients exposed to nucleoside reverse-transcriptase inhibitors and those naive to antiretroviral treatment. 2008 , 198, 1474-81	22
290	Nephrotoxicity. 291-310	1
289	Metabolic complications of antiretroviral therapy in HIV-infected children. 2008 , 4, 37-49	11

288	Low dose versus high dose stavudine for treating people with HIV infection. 2008,	
287	Recent developments in the clinical pharmacology of anti-HIV nucleoside analogs. 2008, 3, 258-65	8
286	[(13)C]Methionine breath test as a marker for hepatic mitochondrial function in HIV-infected patients. 2009, 25, 1243-8	2
285	Novel nucleotide human immunodeficiency virus reverse transcriptase inhibitor GS-9148 with a low nephrotoxic potential: characterization of renal transport and accumulation. 2009, 53, 150-6	51
284	Mitochondrial DNA depletion in rat liver induced by fosalvudine tidoxil, a novel nucleoside reverse transcriptase inhibitor prodrug. 2009, 53, 2748-51	7
283	Retention of metabolites of 2β-Didehydro-3β-deoxy-4β-ethynylthymidine, a novel anti-human immunodeficiency virus type 1 thymidine analog, in cells. 2009, 53, 3317-24	8
282	Mitochondrial toxicity in HIV-infected patients both off and on antiretroviral treatment: a continuum or distinct underlying mechanisms?. 2009, 64, 901-9	42
281	Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA). 2009, 49, 892-900	32
280	Impact of novel human immunodeficiency virus type 1 reverse transcriptase mutations P119S and T165A on 4β-ethynylthymidine analog resistance profile. 2009, 53, 4640-6	13
279	Relationship between polymerase gamma (POLG) polymorphisms and antiretroviral therapy-induced lipodystrophy in HIV-1 infected patients: a case-control study. 2009, 7, 244-53	23
278	Pharmacogenetics of nucleoside reverse-transcriptase inhibitor-associated peripheral neuropathy. 2009, 10, 623-37	28
277	Mutations in mitochondrial DNA polymerase-gamma promote breast tumorigenesis. 2009, 54, 516-24	98
276	HIV Therapeutics: Antiretroviral Drugs and Immune-Based Therapies. 2009, 415-514	
275	Cytotoxicological analysis of a gp120 binding aptamer with cross-clade human immunodeficiency virus type 1 entry inhibition properties: comparison to conventional antiretrovirals. 2009, 53, 3056-64	12
274	Nelfinavir/ritonavir reduces acinar injury but not inflammation during mouse caerulein pancreatitis. 2009, 296, G1040-6	20
273	Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study). 2009, 119, 805-11	79
272	Metabolic and cardiovascular complications of HIV. 2009, 37, 348-351	
271	Lipodistrofia relacionada con el VIH-1. 2009, 24, 489-493	1

270	Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA. 2009 , 49, 2080-6	82
269	Proteomic analysis of mitochondrial proteins of basal and lipolytically (isoproterenol and TNF-alpha)-stimulated adipocytes. 2009 , 106, 257-66	20
268	Mutational analysis of the mitochondrial tRNA genes and flanking regions in umbilical cord tissue from uninfected infants receiving AZT-based therapies for prophylaxis of HIV-1. 2009 , 50, 10-26	10
267	Long-term exposure to AZT, but not d4T, increases endothelial cell oxidative stress and mitochondrial dysfunction. 2009 , 9, 1-12	37
266	A comparison of lipoatrophy and aging: volume deficits in the face. 2009 , 33, 14-21	45
265	3D-QSAR Studies on DATAs and DAPYs for HIV-RT Inhibitors using CoMFA and CoMSIA Approaches. 2009 , 28, 218-225	3
264	Comparative study of the persistence of anti-HIV activity of deoxynucleoside HIV reverse transcriptase inhibitors after removal from culture. 2009 , 6, 5	7
263	In vivo assessment of mitochondrial toxicity of metacavir in Rhesus monkeys after three months of intravenous administration. 2009 , 30, 1666-73	7
262	Effect of nucleoside reverse transcriptase inhibitors on CD4 T-cell recovery in HIV-1-infected individuals receiving long-term fully suppressive combination antiretroviral therapy. 2009 , 10, 143-51	3
261	Long term adverse effects related to nucleoside reverse transcriptase inhibitors: clinical impact of mitochondrial toxicity. 2009 , 41, 808-17	32
260	Synthesis and in vitro transdermal penetration of methoxypoly(ethylene glycol) carbonate derivatives of stavudine. 2009 , 5, 497-506	7
259	Oral uridine supplementation antagonizes the peripheral neuropathy and encephalopathy induced by antiretroviral nucleoside analogues. 2010 , 24, 345-52	17
258	Mitochondrial changes during D-drug-containing once-daily therapy in HIV-positive treatment-naive patients. <i>Antiviral Therapy</i> , 2010 , 15, 51-9	1.6 18
257	In utero exposure of female CD-1 Mice to AZT and/or 3TC: I. Persistence of microscopic lesions in cardiac tissue. 2010 , 10, 37-50	11
256	Absence of mitochondrial toxicity in hearts of transgenic mice treated with abacavir. 2010 , 10, 146-51	4
255	Treatment options for mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome. 2010 , 30, 1179-96	33
254	Partial selective inhibition of HIV-1 reverse transcriptase and human DNA polymerases α and β by thiated 3 β -fluorothymidine analogue 5 α -triphosphates. 2010 , 88, 176-81	4
253	Polymerase gamma disease through the ages. 2010 , 16, 163-74	63

252	Pharmacologic effects on mitochondrial function. 2010 , 16, 189-99	36
251	A mechanistic view of human mitochondrial DNA polymerase gamma: providing insight into drug toxicity and mitochondrial disease. 2010 , 1804, 1213-22	22
250	Discovery of GS-9131: Design, synthesis and optimization of amidate prodrugs of the novel nucleoside phosphonate HIV reverse transcriptase (RT) inhibitor GS-9148. 2010 , 18, 3606-17	51
249	Lack of association between stavudine exposure and lipoatrophy, dysglycaemia, hyperlactataemia and hypertriglyceridaemia: a prospective cross sectional study. 2010 , 7, 23	5
248	New and emerging agents in the management of lipodystrophy in HIV-infected patients. 2010 , 2, 167-78	4
247	Abacavir/lamivudine combination in the treatment of HIV: a review. 2010 , 6, 83-94	7
246	Skeletal muscle mitochondrial DNA content and aerobic metabolism in patients with antiretroviral therapy-associated lipoatrophy. 2010 , 65, 1497-504	2
245	Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis b or c virus co-infection. 2010 , 50, 502-11	77
244	Zidovudine-induced myopathy: A study in Indian patients. 2010 , 1, 63-6	5
243	Role of pyrimidine depletion in the mitochondrial cardiotoxicity of nucleoside analogue reverse transcriptase inhibitors. 2010 , 55, 550-7	10
242	Mild improvement in mitochondrial function after a 3-year antiretroviral treatment interruption despite persistent impairment of mitochondrial DNA content. 2010 , 8, 379-85	1
241	Synthesis and in vitro human skin penetration of oligo- and polymeric ethylene glycol carbonates of zidovudine and stavudine. 2010 , 60, 575-82	
240	Discovery and development of anti-HBV agents and their resistance. 2010 , 15, 5878-908	43
239	Nucleoside reverse transcriptase inhibitor toxicity and mitochondrial DNA. 2010 , 6, 1493-504	66
238	HIV/AIDS and auditory function in adults: the need for intensified research in the developing world. 2010 , 9, 1-9	11
237	Mitochondrial changes in cidofovir therapy for BK virus nephropathy. 2010 , 42, 1713-5	6
236	Transplacental Exposure to Antiretroviral Drugs and Cardiotoxicity in Offspring. 2010 , 305-321	
235	The clinical care of the HIV-1-infected infant. 2010 , 37, 873-85, xi	4

234	Genome Stability and Human Diseases. 2010 ,	3
233	Impact of antiretroviral therapy on growth, body composition and metabolism in pediatric HIV patients. 2010 , 12, 187-99	23
232	From old to new nucleoside reverse transcriptase inhibitors: changes in body fat composition, metabolic parameters and mitochondrial toxicity after the switch from thymidine analogs to tenofovir or abacavir. 2011 , 10, 389-406	20
231	Pathophysiological Implications of Altered Redox Balance in HIV/AIDS Infection: Diagnosis and Counteract Interventions. 2011 , 39-70	1
230	Fatal toxicity from symptomatic hyperlactataemia: a retrospective cohort study of factors implicated with long-term nucleoside reverse transcriptase inhibitor use in a South African hospital. 2011 , 34, 521-7	3
229	Mechanisms of drug-induced liver injury: from bedside to bench. 2011 , 8, 202-11	187
228	Human immunodeficiency virus/acquired immunodeficiency syndrome and infertility: emerging problems in the era of highly active antiretrovirals. 2011 , 96, 546-53	53
227	TNFs involved in neuropathic pain induced by nucleoside reverse transcriptase inhibitor in rats. 2011 , 25, 1668-76	29
226	Management of HIV infection in treatment-naive patients: a review of the most current recommendations. 2011 , 68, 991-1001	15
225	Mitochondrial interference by anti-HIV drugs: mechanisms beyond Pol- β inhibition. 2011 , 32, 715-25	96
224	In vitro assessment of the adverse effects of antiretroviral drugs on the human male gamete. 2011 , 25, 485-91	13
223	Mitochondrial DNA Replication in Health and Disease. 2011 ,	1
222	Tenofovir nephrotoxicity: 2011 update. 2011 , 2011, 354908	168
221	Structural insight on processivity, human disease and antiviral drug toxicity. 2011 , 21, 83-91	2
220	Genome-wide analysis of primary CD4+ and CD8+ T cell transcriptomes shows evidence for a network of enriched pathways associated with HIV disease. 2011 , 8, 18	50
219	Brain-derived neurotrophic factor modulates antiretroviral-induced mechanical allodynia in the mouse. 2011 , 89, 1551-65	17
218	Determination of nucleoside analog mono-, di-, and tri-phosphates in cellular matrix by solid phase extraction and ultra-sensitive LC-MS/MS detection. 2011 , 56, 390-401	81
217	Determinants of individual variation in intracellular accumulation of anti-HIV nucleoside analog metabolites. 2011 , 55, 895-903	11

216	INX-08189, a phosphoramidate prodrug of 6-O-methyl-2 β -methyl guanosine, is a potent inhibitor of hepatitis C virus replication with excellent pharmacokinetic and pharmacodynamic properties. 2011 , 55, 1843-51	68
215	Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection. 2011 , 66, 240-50	128
214	Drug-Induced Liver Injury. 2011 , 478-506	
213	Stavudine induced acute necrotizing pancreatitis with tetany in a pediatric patient. 2012 , 44, 523-5	5
212	Painful HIV-associated sensory neuropathy. 2012 , 2, 543-52	27
211	Recent patents on anti-telomerase cancer therapy. 2012 , 7, 102-17	45
210	Nutrition and the HIV-associated lipodystrophy syndrome. 2012 , 25, 267-87	22
209	Effect of HIV-1 infection and sex on the cellular pharmacology of the antiretroviral drugs zidovudine and lamivudine. 2012 , 56, 3011-9	10
208	Incidence of acute pancreatitis in human immunodeficiency virus-positive patients with hypertriglyceridemia: is it really high?. 2012 , 41, 283-9	5
207	Mitochondrial evolution in HIV-infected children receiving first- or second-generation nucleoside analogues. 2012 , 60, 111-6	18
206	An unusual phenotypic and genotypic expression in F2 generation following one stage zidovudine exposure during pregnancy and lactation- an experiment in mice. 2012 , 37, 51-61	
205	Risk factors and outcome of HIV-associated idiopathic noncirrhotic portal hypertension. 2012 , 36, 875-85	40
204	Antiretroviral neurotoxicity. 2012 , 18, 388-99	187
203	Cytosine deoxyribonucleoside anti-HIV analogues: a small chemical substitution allows relevant activities. 2012 , 39, 458-63	7
202	An Update on Drug-induced Liver Injury. 2012 , 2, 247-59	79
201	Drug-Induced Liver Injury. 2012 , 417-461	7
200	Advances in Mitochondrial Medicine. 2012 ,	10
199	Antiretroviral nucleoside analogues suppress antibody synthesis in human B-lymphocytes. <i>Antiviral Therapy</i> , 2012 , 17, 729-35	1.6 2

198	Pathogenesis of HIV-associated sensory neuropathy: evidence from in vivo and in vitro experimental models. 2012 , 17, 19-31	68
197	PGC-1 α modulates the expression of genes involved in mitochondrial function and adipogenesis during preadipocyte differentiation. 2012 , 47, 419-27	8
196	Hepatotoxicity: a scheme for generating chemical categories for read-across, structural alerts and insights into mechanism(s) of action. 2013 , 43, 537-58	66
195	Differential gene expression in HIV-infected individuals following ART. 2013 , 100, 420-8	23
194	Clinical and molecular features of POLG-related mitochondrial disease. 2013 , 5, a011395	94
193	Effects of substitutions at the 4' and 2' positions on the bioactivity of 4'-ethynyl-2-fluoro-2'-deoxyadenosine. 2013 , 57, 6254-64	28
192	Emerging need to use phytopharmaceuticals in the treatment of HIV. 2013 , 6, 218-223	7
191	Metabolic complications and treatment of perinatally HIV-infected children and adolescents. 2013 , 16, 18600	65
190	The Association between Yang-Deficient Constitution and Clinical Outcome of Highly Active Antiretroviral Therapy on People Living with HIV. 2013 , 2013, 201857	5
189	Thymidine analogues suppress autophagy and adipogenesis in cultured adipocytes. 2013 , 57, 543-51	12
188	HIV-related neuropathy: current perspectives. 2013 , 5, 243-51	48
187	Safety of tenofovir during pregnancy for the mother and fetus: a systematic review. 2013 , 57, 1773-81	70
186	Neurotoxicity of antiretroviral therapy. 2013 , 8, 469-475	2
185	Mitochondrial DNA subhaplogroups L0a2 and L2a modify susceptibility to peripheral neuropathy in Malawian adults on stavudine containing highly active antiretroviral therapy. 2013 , 63, 647-52	21
184	Transplacental exposure to AZT induces adverse neurochemical and behavioral effects in a mouse model: protection by L-acetylcarnitine. 2013 , 8, e55753	10
183	Effect of Antiretroviral Drug (arved) on the Kidney in Albino Rat. 2014 , 18, 343	1
182	Effect of antiretroviral drug (arved) on hepatic enzymes in albino rats. 2014 , 18, 351	
181	UPLC-MS Metabonomics Reveals Perturbed Metabolites in HIV-Infected Sera. 2014 , 2, 37-52	2

180	Palm Fruit Juice Mitigates AZT Mitochondrial Genotoxicity and Dose- Dependent Cytotoxicity. 2014 , 5,	2
179	Nonclinical Safety Profile of BMS-986001, a Nucleoside Transcriptase Inhibitor for Combination Retroviral Therapy. 2014 , 33, 204-218	0
178	MMS exposure promotes increased MtDNA mutagenesis in the presence of replication-defective disease-associated DNA polymerase β variants. 2014 , 10, e1004748	17
177	Mitochondrial toxicities of nucleoside analogue reverse transcriptase inhibitors in AIDS cases. 2014 , 35, 96-9	1
176	PharmGKB summary: abacavir pathway. 2014 , 24, 276-82	6
175	HIV treatment and associated mitochondrial pathology: review of 25 years of in vitro, animal, and human studies. 2014 , 42, 811-22	75
174	A review of the toxicity of HIV medications. 2014 , 10, 26-39	197
173	Nano-NRTIs demonstrate low neurotoxicity and high antiviral activity against HIV infection in the brain. 2014 , 10, 177-85	36
172	Idiosyncratic drug-induced liver injury: an update on the 2007 overview. 2014 , 13, 67-81	41
171	A rapid and divergent access to chiral azacyclic nucleoside analogues via highly enantioselective 1,3-dipolar cycloaddition of β -nucleobase substituted acrylates. 2014 , 50, 14809-12	28
170	Peripheral blood mitochondrial DNA/nuclear DNA (mtDNA/nDNA) ratio as a marker of mitochondrial toxicities of stavudine containing antiretroviral therapy in HIV-infected Malawian patients. 2014 , 18, 438-45	6
169	Zidovudine induces visceral mitochondrial toxicity and intra-abdominal fat gain in a rodent model of lipodystrophy. <i>Antiviral Therapy</i> , 2014 , 19, 783-92	1.6 7
168	Mechanical allodynia induced by nucleoside reverse transcriptase inhibitor is suppressed by p55TNFSR mediated by herpes simplex virus vector through the SDF1/CXCR4 system in rats. 2014 , 118, 671-80	20
167	Antiretroviral therapy-induced mitochondrial toxicity: potential mechanisms beyond polymerase- β inhibition. 2014 , 96, 110-20	31
166	Low dose versus high dose stavudine for treating people with HIV infection. 2015 , 1, CD007497	4
165	Persistent Peripheral Nervous System Damage in Simian Immunodeficiency Virus-Infected Macaques Receiving Antiretroviral Therapy. 2015 , 74, 1053-60	16
164	Application of artificial neural network to investigate the effects of 5-fluorouracil on ribonucleotides and deoxyribonucleotides in HepG2 cells. 2015 , 5, 16861	13
163	Drug-Induced Metabolic Acidosis. 2015 , 4,	22

162	Caenorhabditis elegans as a Model System for Studying Drug Induced Mitochondrial Toxicity. 2015 , 10, e0126220	9
161	Drug-induced fatty liver disease: An overview of pathogenesis and management. 2015 , 14, 789-806	48
160	Associations between lipodystrophy or antiretroviral medications and cirrhosis in patients with HIV infection or HIV/HCV coinfection. 2015 , 27, 577-84	8
159	Mechanisms of distal axonal degeneration in peripheral neuropathies. 2015 , 596, 33-50	130
158	Inflammasomes in pancreatic physiology and disease. 2015 , 308, G643-51	33
157	Mitochondrial and apoptotic in vitro modelling of differential HIV-1 progression and antiretroviral toxicity. 2015 , 70, 2330-6	4
156	Setting Clinical Exposure Levels of Concern for Drug-Induced Liver Injury (DILI) Using Mechanistic in vitro Assays. 2015 , 147, 500-14	78
155	Antiretroviral therapy-induced toxicity is associated with increased mRNA expression of telomerase. 2015 , 55, 1119-24	3
154	ASK1 restores the antiviral activity of APOBEC3G by disrupting HIV-1 Vif-mediated counteraction. 2015 , 6, 6945	26
153	Association of circulating cytochrome c with clinical manifestations of antiretroviral-induced toxicity. 2015 , 20, 71-4	9
152	Antiretroviral Agent. 2016 , 169-214	0
151	Hearing Loss in HIV-Infected Children in Lilongwe, Malawi. 2016 , 11, e0161421	19
150	Mutations of mtDNA polymerase- β and hyperlactataemia in the HIV-infected Zulu population of South Africa. 2016 , 106, 1254	
149	Infektiologische Ursachen peripherer Neuropathien. 2016 , 27, 36-44	
148	Identification of transformation products of antiviral drugs formed during biological wastewater treatment and their occurrence in the urban water cycle. 2016 , 98, 75-83	62
147	Effects of BMS-986094, a Guanosine Nucleotide Analogue, on Mitochondrial DNA Synthesis and Function. 2016 , 153, 396-408	10
146	The DNA Polymerase Gamma R953C Mutant Is Associated with Antiretroviral Therapy-Induced Mitochondrial Toxicity. 2016 , 60, 5608-11	5
145	Analysis of the Endogenous Deoxynucleoside Triphosphate Pool in HIV-Positive and -Negative Individuals Receiving Tenofovir-Emtricitabine. 2016 , 60, 5387-92	6

144	Drug induced mitochondrial dysfunction: Mechanisms and adverse clinical consequences. 2016 , 31, 63-74	37
143	Capture of a third Mg ²⁺ is essential for catalyzing DNA synthesis. 2016 , 352, 1334-7	99
142	Discovery and characterization of a second extremely thermostable (+)-lactamase from <i>Sulfolobus solfataricus</i> P2. 2016 , 121, 484-90	12
141	Risk Factors for Incident Diabetes in a Cohort Taking First-Line Nonnucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy. 2016 , 95, e2844	33
140	Intracellular pharmacokinetic study of zidovudine and its phosphorylated metabolites. 2016 , 6, 158-62	6
139	HAART toxicity masquerading as a surgical abdomen. 2016 , 18, 33-6	
138	Insights into the Molecular Mechanism of Polymerization and Nucleoside Reverse Transcriptase Inhibitor Incorporation by Human PrimPol. 2016 , 60, 561-9	19
137	Single- and repeat-dose toxicity of IDX14184, a nucleotide prodrug with antiviral activity for hepatitis C viral infection, in mice, rats, and monkeys. 2016 , 35, 472-90	4
136	Placental Mitochondrial Toxicity, Oxidative Stress, Apoptosis, and Adverse Perinatal Outcomes in HIV Pregnancies Under Antiretroviral Treatment Containing Zidovudine. 2017 , 75, e113-e119	18
135	Ginsenoside Rg3 restores hepatitis C virus-induced aberrant mitochondrial dynamics and inhibits virus propagation. 2017 , 66, 758-771	23
134	Leveraging increased cytoplasmic nucleoside kinase activity to target mtDNA and oxidative phosphorylation in AML. 2017 , 129, 2657-2666	43
133	DNMT1 modulation in chronic hepatitis B patients and hypothetic influence on mitochondrial DNA methylation status during long-term nucleo(t)side analogs therapy. 2017 , 89, 1208-1214	5
132	Virtual Screening of Acyclovir Derivatives as Potential Antiviral Agents: Design, Synthesis, and Biological Evaluation of New Acyclic Nucleoside ProTides. 2017 , 60, 7876-7896	10
131	Liquid chromatography-mass spectrometry methods for the intracellular determination of drugs and their metabolites: a focus on antiviral drugs. 2017 , 409, 5837-5853	3
130	Editor's Highlight: Comparative Renal Safety Assessment of the Hepatitis B Drugs, Adefovir, Tenofovir, Telbivudine and Entecavir in Rats. 2017 , 155, 283-297	7
129	Rapid Onset of Fatal Lactic Acidosis Complicating Tenofovir Therapy in a Diabetic Patient with Cirrhosis: A Cautionary Tale. 2017 , 7, 80-81	4
128	Mitochondrial defects arise from nucleoside/nucleotide reverse transcriptase inhibitors in neurons: Potential contribution to HIV-associated neurocognitive disorders. 2017 , 1863, 406-413	12
127	Identification of benzazole compounds that induce HIV-1 transcription. 2017 , 12, e0179100	1

- 126 Manifestations of Drug Toxicity on Mitochondria in the Nervous System. **2018**, 133-167
- 125 Nephrotoxicity. **2018**, 169-184 2
- 124 Enantioselective Synthesis of Carbocyclic Nucleosides via Asymmetric [3 + 2] Annulation of β Purine-Substituted Acrylates with MBH Carbonates. **2018**, 20, 389-392 13
- 123 Endocrine and Metabolic Emergencies in HIV/AIDS. **2018**, 151-159
- 122 [Nephrotoxicity of antiretrovirals other than tenofovir]. **2018**, 14, 55-66
- 121 Interpretation, Integration, and Implementation of In Vitro Assay Data: The Predictive Toxicity Challenge. **2018**, 345-364 2
- 120 Metabolic health across the BMI spectrum in HIV-infected and HIV-uninfected men. **2018**, 32, 49-57 7
- 119 Diaryl ethers with carboxymethoxyphenacyl motif as potent HIV-1 reverse transcriptase inhibitors with improved solubility. **2018**, 33, 9-16 6
- 118 Transplacental Exposure to Antiretroviral Drugs and Cardiotoxicity in Offspring. **2018**, 326-340
- 117 Examining Relationships between Metabolism and Persistent Inflammation in HIV Patients on Antiretroviral Therapy. **2018**, 2018, 6238978 22
- 116 Vitamin D, Oxidative Stress, and the Antiretroviral Tenofovir. **2018**, 207-217
- 115 ProTide generated long-acting abacavir nanoformulations. **2018**, 54, 8371-8374 15
- 114 Absence of Nosocomial Transmission of Imported Lassa Fever during Use of Standard Barrier Nursing Methods. **2018**, 24, 978-987 5
- 113 Emerging reverse transcriptase inhibitors for HIV-1 infection. **2018**, 23, 149-157 23
- 112 1,3,4-Oxadiazoles as Telomerase Inhibitor: Potential Anticancer Agents. **2018**, 17, 1869-1883 10
- 111 Synthesis of a long acting nanoformulated emtricitabine ProTide. **2019**, 222, 119441 9
- 110 Mitochondrial dysfunctions in HIV infection and antiviral drug treatment. **2019**, 15, 1043-1052 3
- 109 Immunopathologic Effects of Prednisolone and Cyclosporine A on Feline Immunodeficiency Virus Replication and Persistence. **2019**, 11, 4

108	Disorders of the Pancreas. 2019 , 135-148	
107	Mitochondrial dysfunction in HIV-induced peripheral neuropathy. 2019 , 145, 67-82	10
106	HIV and GI Tract Complications. 2019 ,	
105	DNA polymerase- γ hypothesis in nucleoside reverse transcriptase-induced mitochondrial toxicity revisited: A potentially protective role for citrus fruit-derived naringenin?. 2019 , 852, 159-166	2
104	Cardiac and mitochondrial function in HIV-uninfected fetuses exposed to antiretroviral treatment. 2019 , 14, e0213279	9
103	Targeting the Viral Polymerase of Diarrhea-Causing Viruses as a Strategy to Develop a Single Broad-Spectrum Antiviral Therapy. 2019 , 11,	15
102	The thymidine dideoxynucleoside analog, alovudine, inhibits the mitochondrial DNA polymerase γ impairs oxidative phosphorylation and promotes monocytic differentiation in acute myeloid leukemia. 2019 , 104, 963-972	9
101	Multi-Armed Angle-Based Direct Learning for Estimating Optimal Individualized Treatment Rules With Various Outcomes. 2020 , 115, 678-691	11
100	Bile duct ligation enhances AZT CNS toxicity partly by impairing the expression and function of BCRP in rat brain. 2020 , 41, 181-191	4
99	Exposure of Leukocytes to HIV Preexposure Prophylaxis Decreases Mitochondrial Function and Alters Gene Expression Profiles. 2020 , 65,	4
98	Pharmacokinetics of lopinavir/ritonavir oral solution to treat COVID-19 in mechanically ventilated ICU patients. 2020 , 75, 2657-2660	10
97	Didanosine-Associated Retinal Toxicity (DART) Amongst HIV-Positive Patients: a Case Series and Literature Review. 2020 , 2, 2939-2952	2
96	Inhibition of human immunodeficiency virus type 1 by niclosamide through mTORC1 inhibition. 2020 , 6, e04050	2
95	Mitochondrial DNA Parameters in Blood of Infants Receiving Lopinavir/Ritonavir or Lamivudine Prophylaxis to Prevent Breastfeeding Transmission of HIV-1. 2020 , 9,	1
94	Mitochondrial Toxicogenomics for Antiretroviral Management: HIV Post-exposure Prophylaxis in Uninfected Patients. 2020 , 11, 497	6
93	Pharmacokinetics of nucleoside/nucleotide reverse transcriptase inhibitors for the treatment and prevention of HIV infection. 2020 , 16, 551-564	0
92	The Enantioselective Synthesis of Chiral Carbocyclic Nucleosides via Palladium-Catalyzed Asymmetric Allylic Amination of Alicyclic MBH Adducts with Purines. 2020 , 362, 1955-1960	6
91	Prevalence of hearing loss and tinnitus in a group of adults with Human Immunodeficiency Virus. 2020 , 67, e1-e7	0

90	Don't forget ototoxicity during the SARS-CoV-2 (Covid-19) pandemic!. 2020 , 34, 2058738420941754	16
89	Beneficial Effects of Cannabis on Blood-Brain Barrier Function in Human Immunodeficiency Virus. 2021 , 73, 124-129	7
88	The far-reaching HAND of cART: cART effects on astrocytes. 2021 , 16, 144-158	7
87	CNS Neurotoxicity of Antiretrovirals. 2021 , 16, 130-143	14
86	DNA Recognition/Processing Eukaryotic DNA Polymerase β 2021 , 445-452	
85	Structure- and Mechanism-Based Research Progress of Anti-acquired Immune Deficiency Syndrome Drugs. 2021 , 41, 3015	
84	Targeted Metabolomic Assessment of the Sub-Lethal Toxicity of Halogenated Acetic Acids (HAAs) to. 2021 , 11,	4
83	Mitochondrial changes associated with viral infectious diseases in the paediatric population. 2021 , 31, e2232	0
82	HIV in Neonates and Infants. 2021 , 48, 275-292	1
81	Protection of Retinal Function by Nucleoside Reverse Transcriptase Inhibitors Following Retinal Ischemia/Reperfusion Injury. 2021 , 37, 485-491	0
80	Profiling the physiological pitfalls of anti-hepatitis C direct-acting agents in budding yeast. 2021 , 14, 2199-2213	4
79	Human PrimPol Discrimination against Dideoxynucleotides during Primer Synthesis. 2021 , 12,	0
78	Stavudine, Didanosine, and Zalcitabine. 2006 , 77-132	2
77	Neurological Consequences of Antiretroviral Treatment. 2008 , 173-184	1
76	The mitochondrial DNA polymerase in health and disease. 2010 , 50, 211-22	47
75	Iatrogenic mitochondrialopathies: a recent lesson from nucleoside/nucleotide reverse transcriptase inhibitors. 2012 , 942, 347-69	11
74	Drug-Induced Liver Injury. 2018 , 844-890.e17	1
73	Alcohol and HIV Interactions in the Natural History and Treatment of HIV/AIDS. 2005 , 799-818	1

72	Drug-Induced Liver Injury. 2006 , 503-550	3
71	Liver Disease Caused by Drugs. 2010 , 1413-1446.e8	2
70	Large hepatic mitochondrial DNA deletions associated with L-lactic acidosis and highly active antiretroviral therapy. 2001 , 15, 419-20	26
69	Failure of reactivation of hepatitis B after liver transplantation in hepatitis B surface antigen-negative, core antibody-positive recipients. 2002 , 73, 481-2	14
68	Upregulation of Apoptosis Pathway Genes in Peripheral Blood Mononuclear Cells of HIV-Infected Individuals with Antiretroviral Therapy-Associated Mitochondrial Toxicity. 2017 , 61,	3
67	D-learning to estimate optimal individual treatment rules. 2018 , 12,	11
66	HIV-1 polymerase inhibition by nucleoside analogs: cellular- and kinetic parameters of efficacy, susceptibility and resistance selection. 2012 , 8, e1002359	22
65	Mitochondrial toxicity studied with the PBMC of children from the Chinese national pediatric highly active antiretroviral therapy cohort. 2013 , 8, e57223	16
64	Relaxation effect of abacavir on rat basilar arteries. 2015 , 10, e0123043	3
63	Toxicity of novel anti-hepatitis drug bicyclol: a preclinical study. 2005 , 11, 665-71	17
62	An Overview of Mitochondrial Toxicity of Nucleoside Reverse Transcriptase Inhibitors Associated with HIV Therapy. 2005 , 2, 152-162	6
61	Assessment of metabolic syndrome in HIV-infected individuals. 2017 , 38, 152-156	6
60	Metabolic syndrome and cardiovascular disease risk assessment among human immunodeficiency virus-infected individuals on antiretroviral therapy. 2018 , 39, 28-33	2
59	Fatal Tenofovir-Associated Lactic Acidosis: A Case Report. 2015 , 17, e19546	6
58	Neuropsychiatric Effects of Antiviral Drugs. 2020 , 12, e9536	5
57	Mitochondrial Toxicity of Anti-Retroviral Drugs. 2002 , 131-140	
56	Pathogenesis of HIV Lipodystrophy. 2003 , 107-137	
55	Involvement of Apoptosis in Complications of HIV and Its Treatment. 2005 , 405-420	

- 54 Direct Effects of Anti-HIV Therapeutics on Apoptosis. **2005**, 441-445
- 53 Antiviral Agents. **2007**, 889-910
- 52 The Clinical Pharmacology of Nucleoside Reverse Transcriptase Inhibitors. **2007**, 279-294
- 51 Drug-Induced Hyperglycemia and Diabetes Mellitus. **2007**, 513-527
- 50 The Endocrine System. **2008**, 55-74
- 49 Antiretroviral Agents. **2009**, 167-216
- 48 Cardiovascular Toxicities of Life-Saving Drugs: Antiviral Therapy. 313-332
- 47 Zidovudine. **2010**, 2479-2511
- 46 Nitrosative Stress in Diverse Multisystem Diseases. **2012**, 71-215
- 45 Mitochondrial Dysfunction and Lactic Acidosis in HIV Disease. 87-93
- 44 Literaturverzeichnis. **2016**, 223-254
- 43 TENOFOVIR INDUCED HEPATITIS. **2018**, 7, 4693-4694
- 42 Symptoms of Toxicity and Plasma Cytochrome c Levels in Human Immunodeficiency Virus-infected Patients Receiving Anti-retroviral Therapy in Ghana: A Cross-sectional Study. **2020**, 20, 88-97 1
- 41 Drug Induced Liver Injury (Dili) and Non Alcoholic Fatty Liver Disease (Nafld). **2020**, 2,
- 40 Medikament-toxischer Leberschaden (DILI). **2020**, 117-157
- 39 Remdesivir; molecular and functional measures of mitochondrial safety. **2021**, 433, 115783 1
- 38 Mitochondrial Toxicity and Lipodystrophy. **2006**, 281-302
- 37 Peripheral Neuropathy Associated With Nucleoside Reverse Transcriptase Inhibitor Therapy. **2006**, 237-266

36	A prospective, proof-of-concept investigation of KPAX002 in chronic fatigue syndrome. 2015 , 8, 11064-74		3
35	Drug-Induced Liver Injury in HIV Patients. 2006 , 2, 430-437		7
34	Drug-Induced Oxidative Stress and Cellular Toxicity. 2021 , 73-113		
33	Vestibular Cochlear Manifestations in COVID-19 Cases.. 2022 , 13, 850337		0
32	Molnupiravir; molecular and functional descriptors of mitochondrial safety.. 2022 , 442, 116003		1
31	Data_Sheet_1.docx. 2020 ,		
30	Mapping Adverse Outcome Pathways for Kidney Injury as a Basis for the Development of Mechanism-Based Animal-Sparing Approaches to Assessment of Nephrotoxicity. 4,		1
29	Polymerase β s Involved in Mitochondrial DNA Maintenance Processes in Concert with APE1 Activity. 2022 , 13, 879		
28	Antiretroviral Therapy and the Lipodystrophy Syndrome, Part 2: Concepts in Aetiopathogenesis. <i>Antiviral Therapy</i> , 2001 , 6, 145-160	1.6	36
27	An Introduction to Nucleoside and Nucleotide Analogues. <i>Antiviral Therapy</i> , 2001 , 6, 1-14	1.6	21
26	Mitochondria and Lipodystrophy: Where are We Now?. <i>Antiviral Therapy</i> , 2003 , 8, 261-263	1.6	3
25	Uridine Abrogates Mitochondrial Toxicity Related to Nucleoside Analogue Reverse Transcriptase Inhibitors in Hepg2 Cells. <i>Antiviral Therapy</i> , 2003 , 8, 463-470	1.6	42
24	Complications Associated with Nrti Therapy: Update on Clinical Features and Possible Pathogenic Mechanisms. <i>Antiviral Therapy</i> , 2004 , 9, 849-863	1.6	61
23	Challenges for the Clinical Development of New Nucleoside Reverse Transcriptase Inhibitors for HIV Infection. <i>Antiviral Therapy</i> , 2005 , 10, 13-28	1.6	13
22	Mitochondrial Studies in Haart-Related Lipodystrophy: From Experimental Hypothesis to Clinical Findings. <i>Antiviral Therapy</i> , 2005 , 10, 73-81	1.6	4
21	Nucleoside Reverse Transcriptase Inhibitors, Mitochondrial Dna and Aids Therapy. <i>Antiviral Therapy</i> , 2005 , 10, 13-27	1.6	26
20	Mitochondrial Toxicity of Nucleoside Analogues in Primary Human Lymphocytes. <i>Antiviral Therapy</i> , 2005 , 10, 327-334	1.6	22
19	Uridine in the Prevention and Treatment of Nrti-Related Mitochondrial Toxicity. <i>Antiviral Therapy</i> , 2005 , 10, 117-123	1.6	13

18	Possible Ways Nucleoside Analogues Can Affect Mitochondrial Dna Content and Gene Expression during HIV Therapy. <i>Antiviral Therapy</i> , 2005 , 10, 3-11	1.6	12
17	Metabolic and Mitochondrial Effects of Switching Antiretroviral-Experienced Patients to Enfuvirtide, Tenofovir and Saquinavir/Ritonavir. <i>Antiviral Therapy</i> , 2006 , 11, 625-630	1.6	6
16	Relationship of Mitochondrial DNA Depletion and Respiratory Chain Activity in Preadipocytes treated with Nucleoside Reverse Transcriptase Inhibitors. <i>Antiviral Therapy</i> , 2007 , 12, 205-216	1.6	16
15	The Influence of HIV Infection and Antiretroviral Therapy on the Mitochondrial Membrane Potential of Peripheral Mononuclear Cells. <i>Antiviral Therapy</i> , 2007 , 12, 769-778	1.6	6
14	Mitochondrial Toxicity of Tenofovir, Emtricitabine and Abacavir Alone and in Combination with Additional Nucleoside Reverse Transcriptase Inhibitors. <i>Antiviral Therapy</i> , 2007 , 12, 1075-1086	1.6	78
13	Uridine Abrogates the Adverse Effects of Antiretroviral Pyrimidine Analogues on Adipose Cell Functions. <i>Antiviral Therapy</i> , 2006 , 11, 25-34	1.6	46
12	Uridine Supplementation for the treatment of Antiretroviral Therapy-Associated Lipoatrophy: A Randomized, Double-Blind, Placebo-Controlled Trial. 2007 , 12, 97-106		12
11	Remdesivir does not affect mitochondrial DNA copy number or deletion mutation frequency in aged male rats.		
10	The Potential of Spirulina platensis to Ameliorate the Adverse Effects of Highly Active Antiretroviral Therapy (HAART). <i>Nutrients</i> , 2022 , 14, 3076	6.7	o
9	Novel Nanotechnology-Based Approaches for Targeting HIV Reservoirs. 2022 , 14, 3090		o
8	Hearing impairment in children living with HIV in Haiti. 2022 , 162, 111329		o
7	Sarcopenia among people living with HIV and the effect of antiretroviral therapy on body composition. 2022 , 101, e31349		o
6	Remdesivir does not affect mitochondrial DNA copy number or deletion mutation frequency in aged male rats: A short report. 2022 , 17, e0271850		o
5	A Rationale and Approach to the Development of Specific Treatments for HIV Associated Neurocognitive Impairment. 2022 , 10, 2244		o
4	The effects of HIV and the antiretrovirals on the mitochondria. 2023 , 351-378		o
3	HIV Replication Increases the Mitochondrial DNA Content of Plasma Extracellular Vesicles. 2023 , 24, 1924		o
2	Pathophysiology and mechanisms of hearing impairment related to neonatal infection diseases. 14,		o
1	Toxic Medications in Mitochondrial Optic Neuropathies. 2023 ,		o

